Procurement Summary
Country: USA
Summary: Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Deadline: 22 Sep 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 123584070
Document Ref. No.: HT9402-25-Q-9401
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
a. Class Insulins, Subclass Rapid Acting Agents U-100
Admelog Apidra Fiasp Humalog Insulin Aspart Insulin Lispro Lyumjev Novolog Merilog b. Class Insulins, Subclass Rapid Acting Agents U-200
Lyumjev Kwikpen U-200 Humalog Kwikpen U-200c. Class Metabolic Dysfunction Agents, Subclass Injectable Diabetic Agents
Bydureon Bcise Byetta Exenatide Mounjaro Ozempic Semaglutide Tirzepatide Trulicityd. Class Metabolic Dysfunction Agents, Subclass Injectable Weight Loss Agents
Saxenda Wegovy ZepboundThe RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9401. Pre-quotation teleconference is on July 30, 2025. Details are stated in Part 2.4. Pre-Quotatio...
Active Contract Opportunity
Notice ID : HT9402-25-Q-9401
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEFENSE HEALTH AGENCY (DHA)
Office: DEFENSE HEALTH AGENCY
General Information
Contract Opportunity Type: Solicitation (Original)
Original Published Date: Jul 29, 2025 10:26 am CDT
Original Date Offers Due: Sep 22, 2025 12:00 pm CDT
Inactive Policy: Manual
Original Inactive Date: Jan 24, 2026
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance:
Documents
Tender Notice
RFQ-HT9402-25-Q-9401-CR.pdf
Price-List-Insulins-Rapid-Acting-Agents-U-100.xlsx
Price-List-Insulins-Rapid-Acting-Agents-U-200.xlsx
Price-List-Metabolic-Dysfunx-Inj-Diabetic.xlsx
Price-List-Metabolic-Dysfunx-Inj-Weight-Loss.xlsx
Price-List-FAQ-Class-Review.pdf
Nov-2025-P-and-T-Meeting-Reporting.xlsx